XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix™.
Xilonix, a True Human™ monoclonal antibody therapy, is being evaluated in advanced colorectal cancer patients where disease is further complicated with cachexia. The primary endpoint of the study is overall survival, comparing survival in Xilonix treated patients to a control population provided only palliative therapy for cachexia.
XBiotech recently conducted an interim analysis of the 40 patients that have entered the study to date. Over half of the patients have succumbed to disease, enabling what the Company says is a preliminary analysis of study endpoints. At the time of analysis, patients receiving Xilonix had a hazard ratio for risk of death of 0.33 (p=0.11) compared with controls. The strong hazard ratio reveals a marked trend for improved survival in the Xilonix treated group compared to controls.
http://clinicaltrials.gov/ct2/show/NCT0 ... nix&rank=1